The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.0, a high ...

Blepharitis is a common chronic condition that affects the eyelids, causing inflammation along the eyelid margins.

Tarsus Pharmaceuticals' lotilaner shows strong market performance for Demodex blepharitis, but cautious investment due to ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Eyelash mites might sound like something out of a horror story, but they’re more common than you think. These microscopic ...

Combined ivermectin and intense pulsed light therapy can help resolve Demodex blepharitis and prevent its recurrence.

Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...

Ocular rosacea affects about 20% of people with rosacea. The eyelids may appear swollen and red and develop crusty debris. The eyes often appear red or bloodshot and can feel irritated. Some people ...

Tarsus Pharmaceuticals, which has more than 100 of its 331 employees in Orange County, has plans to double its office space in Irvine by relocating to a new 60,000-square-foot corporate headquarters ...

This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex blepharitis, generating over $113 million in sales. Tarsus is also pursuing ...

Groundbreaking data from the Ersa and Rhea clinical trials for the treatment of Demodex blepharitis (DB) in patients with Meibomian Gland Disease (MGD) further underscore the utility of XDEMVY broadly ...